#80 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians need awareness of parental cannabis use for behavioral management in children, as unsupervised home administration bypasses medical oversight and exposes pediatric patients to unknown dosing, contaminant risks, and potential legal consequences. This case highlights the critical gap between perceived safety of cannabis and evidence-based pediatric behavioral interventions, underscoring clinicians’ role in educating families about established treatments for childhood behavioral disorders and the risks of unregulated cannabis use in minors.
This case report highlights a concerning public health issue in which parents administered cannabis to children to manage behavioral symptoms without medical supervision or guidance. The incident underscores the gap between informal, parental use of cannabis for behavioral management and evidence-based pediatric treatment approaches, raising important questions about how clinicians should counsel families regarding cannabis use in children. While some parents may perceive cannabis as a benign or natural alternative to conventional medications for attention or behavioral disorders, there is currently limited evidence supporting its safety or efficacy in pediatric populations, and such unsupervised use carries risks of adverse effects and legal consequences. This case demonstrates the need for clinicians to proactively discuss cannabis with families of children with behavioral or neurodevelopmental conditions, establishing clear safety guidelines and evidence-based alternatives. Physicians should be prepared to address parental interest in cannabis therapeutically by providing accurate information about the lack of pediatric evidence, potential harms, and approved treatment options for common behavioral concerns. Clinicians caring for children and adolescents should routinely counsel families that cannabis use in minors remains illegal in most jurisdictions and lacks established safety data, while offering evidence-based behavioral and pharmacological interventions instead.
“When parents resort to giving cannabis to children for behavioral management, it signals a broader failure in our healthcare system to provide accessible evidence-based treatments for pediatric behavioral and neurodevelopmental conditions, and we need to address that gap through legitimate clinical pathways rather than blame families who are desperate for solutions.”
🔴 While media reports of parents administering cannabis to children typically reflect cases of poor judgment rather than evidence-based practice, they highlight a broader clinical concern about self-medication in pediatric behavioral and neurodevelopmental conditions. The lack of pediatric safety and efficacy data for cannabis, combined with potential risks to developing brains, makes it an inappropriate treatment choice, yet some families may turn to it out of desperation when conventional therapies are unavailable, unaffordable, or perceived as ineffective. Clinicians should recognize that parental use of cannabis for child behavior management signals either inadequate access to evidence-based care (such as behavioral therapy, psychoeducation, or FDA-approved medications) or unmet educational needs about cannabis risks in this population. A practical response is to proactively discuss cannabis with families of children presenting with ADHD, anxiety, or behavioral disorders, clarifying both legal consequences and developmental risks while ensuring they have
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
